Eric Lefkofsky: Harnessing Big Data To Aid Cancer Research

Doctors draw on their previous experience when deciding which cancer treatment to recommend for patients, however, Eric Lefkofsky wants physicians to also have access to the outcome data from people with a similar DNA and RNA makeup as their patient. Until now, drawing on both therapeutic data and genomic information to determine the most effective therapies requires obtaining a grant and then performing a study.

Lefkofsky founded Lightbank, a VC firm, and then started Tempus, a company that enables doctors to make data-driven treatment decisions in real-time. Tempus, one of Lightbank’s startups, aggregated big data into a database using proprietary algorithms to give doctors a way to personalize their patient’s treatment plans.

Lefkofsky donates generously to cancer research through the Lefkofsky Family Foundation. Institutions benefiting from the Lefkofsky’s largess include the Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Stanford University; the University of Michigan and New York’s Weill Cornell Medicine. By founding Tempus, Lefkofsky is doing more than donating money; he is enabling doctors to tailor treatment for patients based on their genetic make-up. Seeing cancer researchers collect overwhelming amounts of data looking for patterns, Lefkofsky knew that he could help them analyze all of the data. Lefkofsky and his wife also donate to the arts; they have provided Chicago’s Museum of Contemporary Art with a grant to offer free admission for youth.

Chicago’s notable entrepreneur co founded Groupon, and multiple other companies including Uptake Technologies and Echo Global Logistics. He has taken three of his companies public, including Groupon, InnerWorkings and Echo Global Logistics.

Lefkofsky currently serves as Groupon’s chairman and as CEO of Tempus. Involvement in his community is important to Lefkofsky; he serves as a trustee of The Museum of Science and Industry, Lurie Children’s Hospital of Chicago, World Business Chicago and The Art Institute of Chicago to learn more: click here.

Clay Siegall: The Revolutionary Oncologist Cum Entrepreneur


Clay Siegall is the brain behind Seattle Genetics, a company whose primary objective is to develop cancer remedies. As of the moment, Clay is the incumbent president and CEO of the firm. Using his in-depth scientific knowledge, Clay has transformed Seattle Genetics into a leading oncology research institution as well as supporting philanthropic causes. Under his stewardship, the company has broken new grounds in developing antibody-drug conjugates, including ADCETRIS, an internationally acclaimed drug.


Moreover, Clay has overseen several mergers with an array of leading pharmaceutical enterprises. Among the leading corporations that Seattle Genetics has teamed up with are GlaxoSmithKline and Roche. These transactions have proven to be lucrative to Seattle Genetics, netting the firm an enormous $350 million worth of revenue. Besides, Clay has demonstrated his unparalleled entrepreneurial nous by masterminding record-breaking fundraisers, including an extremely prosperous IPO in 2001.



Clay Siegall boasts of an impressive career recording, having served in different capacities in multiple prominent institutions. Before inaugurating Seattle Genetics, he worked for a substantial period under Bristol-Myers Squibb. Other notable firms in Siegall’s work portfolio include National Cancer Institute and National Institute of Health. Furthermore, Claus sits on various boards, such as the Washington Roundtable.

In his illustrious career, numerous prestigious accolades have been bestowed on Clay. Some of the outstanding awards include the Entrepreneur of the Year, bequeathed by Ernst &Young, and Alumnus of the Year, conferred by the University of Maryland.


The idea of Seattle Genetics was incepted with the aim of mitigating the effects of cancer on patients. At a tender age, Clay experienced the tribulations of cancer patients, as his father was a victim of the condition. At that time, the resources allocated towards combatting the cancer menace were not only scanty but also incompetent. This spurred him to pursue further education on oncology, a dream that was realized after he received a doctorate from the George Washington University.


Since graduating, Clay has maintained his dedication towards finding a lasting solution to this disease. His advice to young entrepreneurs is to interact with established business persons, as they best source for learning new developmental strategies.


Also, Clay Siegall ascribes his unprecedented prosperity to teaming up with like-minded parties. He disclosed that through partnerships, his firm had embraced new techniques, which have resulted in better customer treatment.